IRF7, a central activator of the interferon type 1 immune response, has oncogenic properties and was shown to both influence tumor growth and malignant transformation in diverse tumor types [39] and to regulate myeloid-derived suppressor cell development in cancer [40]. The gene discussed is IRF7; the disease is neoplasm.